Boards are sold as part-time oversight. In the latest board disclosures in our warehouse, the median recurring board payroll is $2.81 million. The 10 highest-paid boards in our screened sample all clear $5.2 million a year.
This draft adapts our March 17, 2026 Voronoi post Ranked: The 10 Highest-Paid Corporate Boards into a fuller web article. To keep the ranking focused on recurring board cost rather than one-time windfalls, we excluded any individual director payout above $1 million and kept boards with 5 to 15 seats.
Key takeaways
- The screened sample covers 300 companies, with a median board payroll of $2.81 million.
- Regeneron leads the ranking at $7.05 million, or about 2.5x the sample median.
- Six of the top 10 boards come from biotech or pharma companies, showing how expensive specialized oversight can get.
- Even inside the top 10, board size is not the whole story. argenx and Ionis crack the list with only nine directors because the pay per seat is so high.
Ranked: The 10 Highest-Paid Corporate Boards
- Regeneron: $7.05M across 11 directors in FY2025, or about $641K per seat.
- BridgeBio Pharma: $6.65M across 11 directors in FY2024, or about $605K per seat.
- Jazz Pharmaceuticals: $6.05M across 13 directors in FY2024, or about $465K per seat.
- Moderna: $5.75M across 10 directors in FY2024, or about $575K per seat.
- Bank of America: $5.59M across 12 directors in FY2024, or about $466K per seat.
- ExxonMobil: $5.58M across 12 directors in FY2025, or about $465K per seat.
- BlackRock: $5.49M across 15 directors in FY2024, or about $366K per seat.
- Qualcomm: $5.33M across 14 directors in FY2025, or about $381K per seat.
- argenx: $5.24M across 9 directors in FY2024, or about $582K per seat.
- Ionis Pharmaceuticals: $5.23M across 9 directors in FY2024, or about $581K per seat.
The list is not just a mega-cap story. Bank of America, ExxonMobil, Qualcomm, and BlackRock are there, but the upper tier is crowded with drugmakers and life-science companies. Those boards tend to pay more for deep technical expertise, committee work, and equity-heavy packages.
What this ranking is actually measuring
Raw board compensation data can get noisy fast. Some years include founder grants, transition awards, or unusual director elections that swamp the normal annual cost of governance. That is why this adapted ranking screens out any single director row above $1 million.
Once you strip out those one-off spikes, a clearer pattern appears: recurring board cost is usually a low-single-digit-million-dollar line item, but a meaningful slice of boards now run past $5 million a year. That matters because the people approving CEO pay and capital allocation are themselves sitting inside a well-paid market.
Why shareholders should care
- Board pay is sticky. Once cash retainers and equity grants move up, they rarely move back down.
- Per-seat cost shapes incentives. A director collecting $400K to $600K a year is not operating in the same incentive environment as a truly symbolic overseer.
- The board sets the tone for everyone else. A generous board-pay philosophy often sits next to a generous CEO-pay philosophy.
Methodology and source
Source inspiration: our Voronoi post Ranked: The 10 Highest-Paid Corporate Boards, published on March 17, 2026. This rentseek.ing draft uses each company's latest board-compensation disclosure in the warehouse, keeps boards with five to 15 directors, and excludes individual director rows above $1 million so one-time awards do not overwhelm recurring board cost. All figures trace back to SEC proxy filings processed by rentseek.ing.
For a plain-English breakdown of how director pay works, see How Board Directors Get Paid.